Please assess the completion status of the following clinical trial:

Trial Title: Patient-Reported Outcome Of Facial Erythema (PROOF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects age of 18 years or older~* A clinical diagnosis of facial rosacea~* A Patient Self-Assessment score of 4 (severe) at Baseline prior to the study drug application~* A Clinician's Erythema Assessment (CEA) score of 3 (moderate) or 4 (severe) at Baseline prior to the study drug application~Exclusion Criteria:~* More than 5 facial inflammatory lesions (papules or pustules) of rosacea~* Any uncontrolled chronic or serious disease or medical condition that may either interfere with the interpretation of the clinical trial results, or put the subject at significant risk if the subject participates in the clinical trial as judged by the investigator~* Known or suspected allergies or sensitivities to any component of the study drugs, including the active ingredient brimonidine tartrate (see Investigator's Brochure)~* Female who is pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brimonidine tartrate 0.5% gel (Type: EXPERIMENTAL): Participants applied brimonidine tartrate 0.5% gel topically once daily for 8 days.
- Vehicle (Type: PLACEBO_COMPARATOR): Participants applied brimonidine tartrate vehicle gel topically once daily for 8 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).